Bruker Corporation (NASDAQ:BRKR) Given Average Recommendation of “Hold” by Brokerages

Bruker Corporation (NASDAQ:BRKR) has been given an average recommendation of “Hold” by the fifteen research firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $50.3846.

A number of analysts have commented on BRKR shares. Guggenheim boosted their target price on Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Bank of America lifted their price target on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Barclays decreased their price objective on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Citigroup dropped their target price on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a report on Friday, February 13th. Finally, TD Cowen cut their target price on shares of Bruker from $53.00 to $43.00 and set a “hold” rating for the company in a research report on Friday, February 13th.

Insider Activity

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $49.20, for a total transaction of $98,400.00. Following the completion of the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $6,319,395.60. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 27.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently made changes to their positions in BRKR. Orbis Allan Gray Ltd raised its position in Bruker by 5.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock valued at $702,256,000 after purchasing an additional 761,258 shares during the period. State Street Corp grew its stake in shares of Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock valued at $180,700,000 after buying an additional 91,706 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the period. Sculptor Capital LP lifted its position in Bruker by 18.3% during the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after acquiring an additional 476,363 shares in the last quarter. Finally, Brown Advisory Inc. boosted its holdings in Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after acquiring an additional 336,026 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Bruker stock opened at $39.89 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The business has a 50 day simple moving average of $45.84 and a 200-day simple moving average of $40.73. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22. The stock has a market capitalization of $6.06 billion, a PE ratio of -265.93, a price-to-earnings-growth ratio of 2.38 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). The business had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts predict that Bruker will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is -133.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.